FundedIQ
Biotechnology

Theratechnologies: Funding, Investors & Team (Sep 2026)

Theratechnologies Inc., a biopharmaceutical organization, takes part in the revelation of restorative items for commercialization. The organization's restrictive innovations incorporate Long Acting Peptides, a peptide adjustment innovation that expands the objective protein's protection from enzymatic debasement. Its lead item is tesamorelin, which finished its stage III clinical preliminary for the treatment of HIV-related lipodystrophy and is in stage II clinical preliminaries for the treatment of gentle mental debilitation and development chemical lacking stomach stoutness. The organization likewise creates Acute kidney injury, a preclinical stage item. It has a permit concurrence with PDC Biotech GmbH to utilize the main bad guys of the prostaglandin F2a receptor in pre-term work and essential dysmenorrheal; and OctoPlus N.V. to create and popularize GLP-1 arrangement of analogs. The organization likewise has a cooperation and permitting concurrence with EMD Serono, Inc. for the treatment of overabundance stomach fat in HIV-contaminated patients with lipodystrophy. The organization was established in 1993 and is settled in Montreal, Canada.

www.theratech.com LinkedIn Montréal, Canada 51-100 employees
Biotechnology Pharmaceutical Therapeutics B2B
Total raised
$52.5M
Rounds
2
Latest
Undisclosed round
Oct 2023

Theratechnologies has raised $52.5M across 2 funding rounds on record, the most recent an undisclosed round of $12.5M announced in Oct 2023.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Theratechnologies Company Profile and Key Stats

Total funding raised
$52.5M
across 2 rounds on record
Funding rounds on record
2
Latest funding round
Undisclosed round
$12.5M in Oct 2023
Employees
51-100
reported band
Headquarters
Montréal, Canada

Latest funding round on record: Oct 2023.

Theratechnologies Funding Rounds

Date
Round
Amount
Undisclosed round
$12.5M
Post-IPO Debt
$40.0M

Theratechnologies raised $40.0M in a Post-IPO Debt announced in Jul 2022.

1.3 years later, an undisclosed round of $12.5M was announced in Oct 2023.

Theratechnologies Founders and Leadership Team

Name
Role
Contact
John Michel T Huss
CEO
Paul Levesque
CEO
Locked

Contact details for the Theratechnologies team: 1 of 2 have an email address on file.

Start 14-day free trial →

Theratechnologies Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
3,086
$2.2M

Theratechnologies' latest round of $12.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Theratechnologies in Biotechnology and Montréal

Companies Similar to Theratechnologies

Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…

Undisclosed round $4.4M

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…

Undisclosed round $50.0M

Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…

Undisclosed round $260k

Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…

Undisclosed round $430k

Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…

Undisclosed round $2.5M

ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…

Undisclosed round $360k

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…

Undisclosed round $3.1M

Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…

Undisclosed round $15.9M

ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…

Undisclosed round $1.8M

Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…

Undisclosed round $720k

NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…

Undisclosed round $60.0M

ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…

Undisclosed round $190k

Theratechnologies Funding FAQs

What does Theratechnologies do?

Theratechnologies Inc., a biopharmaceutical organization, takes part in the revelation of restorative items for commercialization. The organization's restrictive innovations incorporate Long Acting Peptides, a peptide adjustment innovation that expands the objective protein's protection from enzymatic debasement. Its lead item is tesamorelin, which finished its stage III clinical preliminary for the treatment of HIV-related lipodystrophy and is in stage II clinical preliminaries for the treatment of gentle mental debilitation and development chemical lacking stomach stoutness. The organization likewise creates Acute kidney injury, a preclinical stage item. It has a permit concurrence with PDC Biotech GmbH to utilize the main bad guys of the prostaglandin F2a receptor in pre-term work and essential dysmenorrheal; and OctoPlus N.V. to create and popularize GLP-1 arrangement of analogs. The organization likewise has a cooperation and permitting concurrence with EMD Serono, Inc. for the treatment of overabundance stomach fat in HIV-contaminated patients with lipodystrophy. The organization was established in 1993 and is settled in Montreal, Canada.

How much funding has Theratechnologies raised?

Theratechnologies has raised $52.5M across 2 rounds on record. The most recent is an undisclosed round of $12.5M announced in Oct 2023.

When did Theratechnologies last raise funding?

Theratechnologies' most recent funding round on record is an undisclosed round of $12.5M, announced in Oct 2023.

Who is the CEO of Theratechnologies?

John Michel T Huss is listed as CEO at Theratechnologies.

Where is Theratechnologies headquartered?

Theratechnologies is based in Montréal, Quebec, Canada.

How many employees does Theratechnologies have?

Theratechnologies is in the 51-100 employee band.

How does Theratechnologies' funding compare to other Biotechnology startups?

Theratechnologies' latest round of $12.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's Theratechnologies Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Theratechnologies is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.